FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:612-614 August 7, 2003 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Euvrard, S. PubMed Citation

To the Editor: Euvrard et al. (April 24 issue)¹ note that adjuvant radiotherapy may be useful in the management of squamous-cell carcinoma. Primary irradiation is not mentioned as a therapeutic option. Although surgery may be preferable, radiotherapy should also be given consideration. Candidates for radiotherapy include patients who cannot undergo surgery for medical reasons, patients with large lesions for whom surgery may be functionally or cosmetically disfiguring, and patients who wish to consider a noninvasive therapeutic option.

Regarding the management of cutaneous T-cell lymphomas, the authors state that current treatment is "unsatisfactory." Rituximab, bexarotene, and denileukin diftitox are described by . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.